ArticleFrontiers in pharmacology2025

Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma.

Liangliang Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.